Polypeptides isolated from brevibacterium aurantiacum and their use for the treatment of cancer
AssigneesInstitut National De La Sante Et De La Recherche Medicale (Inserm), INRA (Institut National de la Recherche Agronomique), Universite Paris Sud (Paris XI)
InventorsDavid Machover, Pascal Bonnarme
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and pharmaceutical compositions for treating cancer. More specifically, the invention relates to a polypeptide isolated from Brevibacterium aurantiacum that shows methionine gamma-lyase and homocysteinase activities. The present invention also relates to the use of such a polypeptide for the treatment of cancer.
Claims16
A vector comprising a nucleic acid encoding a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof.
A nucleic acid encoding a recombinant polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof.
A host cell, which has been transformed by
- a nucleic acid encoding a recombinant polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof and/or
- a vector comprising a nucleic acid encoding a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof.
A pharmaceutical composition comprising
- i) a recombinant polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof, or a nucleic acid encoding a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof, or a vector comprising said nucleic acid, and
- ii) a pharmaceutically acceptable carrier.
A recombinant polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof contained in a vector.
A polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof which is covalently conjugated with at least one polyethylene glycol group.
A polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof which is covalently coupled to a tumor targeting agent.
A method of producing a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1, which method comprises the steps of:
- i) culturing a host cell transformed by
- a) a nucleic acid encoding a recombinant polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof,
- and/or
- b) a vector comprising a nucleic acid encoding a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof,
- under condition suitable to allow expression of said polypeptide;
- and
- (ii) recovering the expressed polypeptide.
A method for treating a cancer in a subject of need thereof comprising the step of administering to said subject a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof.
A method for treating a cancer in a subject of need thereof comprising the step of administering to said subject a nucleic acid encoding a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof, or a vector comprising said nucleic acid.
A method for treating a cancer in a subject of need thereof comprising the step of administering to said subject a combination of
- i) a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof, or a nucleic acid encoding a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof, or a vector comprising said nucleic acid, and
- ii) one or more agents selected from the group consisting of:
- one or more enzyme cofactors and one or more chemotherapeutic or radiotherapeutic agents.
Dependencies are inferred from the claim text.